Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)

Inclusion Criteria:

Subject inclusion criteria for the signs and symptoms (S/S), at risk (A/R), HAV test ordered, and Acute HAV Infection cohorts:

• Subjects ≥ 2 years of age

• Subject or legal guardian has signed the Informed Consent Form (ICF) (a minor mayneed to sign an Assent Form (AF) if required by IRB)

• Subjects who are willing to donate the required amount of blood

• Subjects qualified for one (1) or more of the following four (4) Cohorts:

• Signs and symptoms (S/S);

• At risk (A/R);

• Presumed S/S or A/R (HAV test ordered) and

• Acute HAV Infection (known anti-HAV IgM positive samples) - these samples arenot subject to the individual informed consent and volume criteria.

Subject inclusion criteria for the vaccination cohort

• Subjects 2 years of age or older

• Subjects able to understand and willing to sign the ICF at both pre and postvaccination time points. Subject or legal guardian has signed the Informed ConsentForm (a minor may need to sign an assent form if required by IRB)

• Subjects who are willing to donate the required amount of blood: 30 mL

• Subjects with no signs or symptoms of hepatitis as determined by a medical provider,no history of known exposure to HAV

• Subjects previously unvaccinated for HAV

Exclusion Criteria:

• Subjects who previously participated in the study

• Subjects who have received experimental or investigational drugs or treatmentswithin four weeks of phlebotomy

Note for vaccination study: Subjects were screened for anti-HAV prior to vaccination, if positive they were excluded from the study.